Mark Hamalainen is a scientist, serial entrepreneur, and community builder with over twenty years of experience in longevity biotechnology and related fields. His first research experience was as a summer undergraduate research fellow at Caltech in 2004. At the University of Cambridge, his graduate work focused on gene therapy to complement mitochondrial DNA mutations, funded by the Methuselah Foundation. As a serial entrepreneur Mark pivoted from academic research to technology development on the founding teams of the biotechnology startups Halcyon Molecular, Synthego, and OpenCures. In 2021, he again pivoted, this time to community building, recognizing that the major bottleneck to progress was a lack of talent and funding directed to sufficiently ambitious projects versus incremental steps. Mark co-founded the Longevity Biotech Fellowship (LBF), a nonprofit community recruiting, educating and supporting top talent to the mission of solving aging. At the LBF he led development of its Longevity Acceleration Roadmap, which emphasizes Replacement, Reversible Cryostasis, and Gene Delivery as the critical necessary technologies for radical life extension. Through the LBF’s eight cohorts he has advised hundreds of members and companies on research, recruiting, fundraising and startup growth. Mark has spoken at Aging Research and Drug Discovery, Longevity Summit Dublin, Foresight Vision Weekend, and Vitalist Bay. In Oct 2024 he joined ARPA-H as a contracted technical advisor for program manager Jean Hebert. Mark has and will continue to dedicate his career to solving aging, by identifying technical and social bottlenecks to progress and both directly working on them and recruiting others to the cause.